I get the feeling NTI doesn't agree with you re orphan drug status. You have mentioned before that getting FDA approval is a very long process. Attaining orphan drug status helps to fast track that process as far as I am aware? So, I would think attaining that status should be a positive and give some sort or appreciation to the shareprice, how much that is, I'm not sure.
I guess with Fenix, NTI thought this way forward with them is a best outcome for the company...otherwise, why would they be doing it? If Fenix hit those targets then, the company is moving fwd and the shareprice should be up....
I get the feeling NTI doesn't agree with you re orphan drug...
Add NTI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
-0.002(2.56%) |
Mkt cap ! $78.33M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 8.0¢ | 7.6¢ | $69.19K | 889.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 224522 | 7.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 29816 | 2 |
View Market Depth
| Last trade - 14.40pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
-0.002 ( 2.56 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 8.0¢ | 7.6¢ | 390077 | ||
| Last updated 14.30pm 22/05/2024 ? | |||||
| NTI (ASX) Chart |